{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:59Z","timestamp":1789084859748,"version":"build-2803163510"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Dependence"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.drugalcdep.2020.108366","type":"journal-article","created":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T01:15:20Z","timestamp":1603156520000},"page":"108366","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["Quetiapine treatment for cannabis use disorder"],"prefix":"10.1016","volume":"218","author":[{"given":"John J.","family":"Mariani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Pavlicova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Jean Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cale","family":"Basaraba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth M.","family":"Carpenter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy L.","family":"Mahony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Bisaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasir","family":"Naqvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward V.","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances R.","family":"Levin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drugalcdep.2020.108366_bib0005","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1001\/jamapsychiatry.2013.3947","article-title":"Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial","volume":"71","author":"Allsop","year":"2014","journal-title":"JAMA Psychiatry"},{"issue":"17","key":"10.1016\/j.drugalcdep.2020.108366_bib0010","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1001\/jama.295.17.2003","article-title":"Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial","volume":"295","author":"Anton","year":"2006","journal-title":"JAMA"},{"issue":"Suppl. 1","key":"10.1016\/j.drugalcdep.2020.108366_bib0015","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1046\/j.1360-0443.97.s01.1.x","article-title":"Cannabis use: consistency and validity of self-report, on-site urine testing and laboratory testing","volume":"97","author":"Buchan","year":"2002","journal-title":"Addiction"},{"issue":"9","key":"10.1016\/j.drugalcdep.2020.108366_bib0020","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1046\/j.1360-0443.1999.94913114.x","article-title":"Marijuana withdrawal among adults seeking treatment for marijuana dependence","volume":"94","author":"Budney","year":"1999","journal-title":"Addiction"},{"issue":"6","key":"10.1016\/j.drugalcdep.2020.108366_bib0025","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1037\/0022-006X.68.6.1051","article-title":"Adding voucher-based incentives to coping skills and motivational enhancement improves outcomes during treatment for marijuana dependence","volume":"68","author":"Budney","year":"2000","journal-title":"J. Consult. Clin. Psychol."},{"issue":"2","key":"10.1016\/j.drugalcdep.2020.108366_bib0030","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1037\/0022-006X.74.2.307","article-title":"Clinical trial of abstinence-based vouchers and cognitive-behavioral therapy for cannabis dependence","volume":"74","author":"Budney","year":"2006","journal-title":"J. Consult. Clin. Psychol."},{"issue":"1","key":"10.1016\/j.drugalcdep.2020.108366_bib0035","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1080\/10550490802408936","article-title":"A preliminary trial: double-blind comparison of nefazodone, bupropion-SR, and placebo in the treatment of cannabis dependence","volume":"18","author":"Carpenter","year":"2009","journal-title":"Am. J. Addict."},{"issue":"November 6","key":"10.1016\/j.drugalcdep.2020.108366_bib0040","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1111\/j.1369-1600.2012.00461.x","article-title":"A human laboratory study investigating the effects of quetiapine on marijuana withdrawal and relapse in daily marijuana smokers","volume":"18","author":"Cooper","year":"2013","journal-title":"Addict. Biol."},{"issue":"1","key":"10.1016\/j.drugalcdep.2020.108366_bib0045","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0740-5472(00)00148-3","article-title":"Clinical profile of participants in a brief intervention program for cannabis use disorder","volume":"20","author":"Copeland","year":"2001","journal-title":"J. Subst. Abuse Treat."},{"issue":"January 1","key":"10.1016\/j.drugalcdep.2020.108366_bib0050","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S2215-0366(18)30427-9","article-title":"Efficacy and safety of a fatty acid amide hydrolase inhibitor (PF-04457845) in the treatment of cannabis withdrawal and dependence in men: a double-blind, placebo-controlled, parallel group, phase 2a single-site randomised controlled trial","volume":"6","author":"D\u2019Souza","year":"2019","journal-title":"Lancet Psychiatry"},{"issue":"8","key":"10.1016\/j.drugalcdep.2020.108366_bib0055","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1111\/j.1530-0277.1996.tb01142.x","article-title":"Assessment of medication compliance in alcoholics through UV light detection of a riboflavin tracer","volume":"20","author":"Del Boca","year":"1996","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.drugalcdep.2020.108366_bib0060","series-title":"Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition (SCID-I\/P): Biometrics Research Department","author":"First","year":"2002"},{"issue":"8","key":"10.1016\/j.drugalcdep.2020.108366_bib0065","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1176\/appi.ajp.2012.12010055","article-title":"A double-blind randomized controlled trial of N-acetylcysteine in cannabis-dependent adolescents","volume":"169","author":"Gray","year":"2012","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2020.108366_bib0070","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.drugalcdep.2017.04.020","article-title":"A randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults","volume":"177","author":"Gray","year":"2017","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2020.108366_bib0075","first-page":"534","author":"Guy","year":"1976"},{"issue":"1","key":"10.1016\/j.drugalcdep.2020.108366_bib0080","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.sleep.2004.07.006","article-title":"Psychometric properties of the medical outcomes study sleep measure","volume":"6","author":"Hays","year":"2005","journal-title":"Sleep Med."},{"key":"10.1016\/j.drugalcdep.2020.108366_bib0085","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.drugalcdep.2008.12.010","article-title":"Reliability and validity of a short form of the Marijuana Craving Questionnaire","volume":"102","author":"Heishman","year":"2009","journal-title":"Drug Alcohol Depend."},{"issue":"1-2","key":"10.1016\/j.drugalcdep.2020.108366_bib0090","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.drugalcdep.2012.08.007","article-title":"Assessment of riboflavin as a tracer substance: comparison of a qualitative to a quantitative method of riboflavin measurement","volume":"128","author":"Herron","year":"2013","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2020.108366_bib0095","doi-asserted-by":"crossref","first-page":"157","DOI":"10.15288\/jsas.2005.s15.157","article-title":"The COMBINE SAFTEE: a structured instrument for collecting adverse events adapted for clinical studies in the alcoholism field","volume":"15","author":"Johnson","year":"2005","journal-title":"J. Stud. Alcohol Suppl."},{"key":"10.1016\/j.drugalcdep.2020.108366_bib0100","doi-asserted-by":"crossref","first-page":"4623","DOI":"10.1007\/s00213-014-3611-5","article-title":"Lithium carbonate in the management of cannabis withdrawal: a randomized placebo-controlled trial in an inpatient setting","volume":"231","author":"Johnston","year":"2014","journal-title":"Psychopharmacology"},{"issue":"9","key":"10.1016\/j.drugalcdep.2020.108366_bib0105","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1038\/sj.npp.1301108","article-title":"Occupancy of striatal and extrastriatal dopamine D2 receptors by clozapine and quetiapine","volume":"31","author":"Kessler","year":"2006","journal-title":"Neuropsychopharmacology"},{"issue":"May 5","key":"10.1016\/j.drugalcdep.2020.108366_bib0110","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1046\/j.1360-0443.2003.00380.x","article-title":"Effects of reducing contingency management values on heroin and cocaine use for buprenorphine- and desipramine-treated patients","volume":"98","author":"Kosten","year":"2003","journal-title":"Addiction"},{"issue":"1","key":"10.1016\/j.drugalcdep.2020.108366_bib0115","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1080\/10550490490265280","article-title":"Pharmacotherapy for marijuana dependence: a double-blind, placebo-controlled pilot study of divalproex sodium","volume":"13","author":"Levin","year":"2004","journal-title":"Am. J. Addict."},{"issue":"1-3","key":"10.1016\/j.drugalcdep.2020.108366_bib0120","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.drugalcdep.2010.12.010","article-title":"Dronabinol for the treatment of cannabis dependence: a randomized, double-blind, placebo-controlled trial","volume":"116","author":"Levin","year":"2011","journal-title":"Drug Alcohol Depend."},{"issue":"6","key":"10.1016\/j.drugalcdep.2020.108366_bib0125","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1111\/add.12108","article-title":"A randomized double-blind, placebo-controlled trial of venlafaxine-extended release for co-occurring cannabis dependence and depressive disorders","volume":"108","author":"Levin","year":"2013","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2020.108366_bib0130","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.drugalcdep.2015.11.025","article-title":"Dronabinol and lofexidine for cannabis use disorder: a randomized, double-blind, placebo-controlled trial","volume":"159","author":"Levin","year":"2016","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2020.108366_bib0135","doi-asserted-by":"crossref","DOI":"10.1001\/jamainternmed.2019.1993","article-title":"Allsop d; agonist replacement for Cannabis dependence (ARCD) study group. \u201cNabiximols for the treatment of Cannabis dependence: a randomized clinical trial","author":"Lintzeris","year":"2019","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.drugalcdep.2020.108366_bib0140","series-title":"Measuring Alcohol Consumption: Psychosocial and Biochemical Methods","author":"Litten","year":"1992"},{"issue":"2-3","key":"10.1016\/j.drugalcdep.2020.108366_bib0145","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.drugalcdep.2010.08.008","article-title":"Quantification and comparison of marijuana smoking practices: blunts, joints, and pipes","volume":"113","author":"Mariani","year":"2011","journal-title":"Drug Alcohol Depend."},{"issue":"4","key":"10.1016\/j.drugalcdep.2020.108366_bib0150","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3109\/00952990.2014.884102","article-title":"Open-label pilot study of quetiapine treatment for cannabis dependence","volume":"40","author":"Mariani","year":"2014","journal-title":"Am. J. Drug Alcohol Abuse"},{"issue":"3","key":"10.1016\/j.drugalcdep.2020.108366_bib0155","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1037\/0022-006X.72.3.455","article-title":"Brief treatments for cannabis dependence: findings from a randomized multisite trial","volume":"72","author":"Marijuana Treatment Project Research Group (MTPRG)","year":"2004","journal-title":"J. Consult. Clin. Psychol."},{"issue":"7","key":"10.1016\/j.drugalcdep.2020.108366_bib0160","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1038\/npp.2012.14","article-title":"A proof-of-concept randomized controlled study of gabapentin: effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults","volume":"37","author":"Mason","year":"2012","journal-title":"Neuropsychopharmacology"},{"issue":"1-2","key":"10.1016\/j.drugalcdep.2020.108366_bib0165","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.drugalcdep.2009.06.022","article-title":"A placebo-controlled trial of buspirone for the treatment of marijuana dependence","volume":"105","author":"McRae-Clark","year":"2009","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2020.108366_bib0170","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1521-0391.2010.00076.x","article-title":"A placebo-controlled trial of atomoxetine in marijuana-dependent individuals with attention deficit hyperactivity disorder","volume":"19","author":"McRae-Clark","year":"2010","journal-title":"Am. J. Addict."},{"key":"10.1016\/j.drugalcdep.2020.108366_bib0175","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.drugalcdep.2015.08.013","article-title":"Buspirone treatment of cannabis dependence: a randomized, placebo-controlled trial","volume":"156","author":"McRae-Clark","year":"2015","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2020.108366_bib0180","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/ajad.12324","article-title":"Vilazodone for cannabis dependence: a randomized, controlled pilot trial","volume":"25","author":"McRae-Clark","year":"2016","journal-title":"Am. J. Addict."},{"key":"10.1016\/j.drugalcdep.2020.108366_bib0185","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/adb.12350","article-title":"Topiramate and motivational enhancement therapy for cannabis use among youth: a randomized placebo-controlled pilot study","volume":"22","author":"Miranda","year":"2016","journal-title":"Addict. Biol."},{"issue":"3","key":"10.1016\/j.drugalcdep.2020.108366_bib0190","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1080\/00952990701313686","article-title":"Citalopram combined with behavioral therapy reduces cocaine use: a double-blind, placebo-controlled trial","volume":"33","author":"Moeller","year":"2007","journal-title":"Am. J. Drug Alcohol Abuse"},{"issue":"Suppl. 13","key":"10.1016\/j.drugalcdep.2020.108366_bib0195","first-page":"5","article-title":"Quetiapine: preclinical studies, pharmacokinetics, drug interactions, and dosing","volume":"63","author":"Nemeroff","year":"2002","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2020.108366_bib0200","first-page":"63","article-title":"Bupropion reduces some of the symptoms of marihuana withdrawal in chronic marihuana users: a pilot study","volume":"6","author":"Penetar","year":"2012","journal-title":"Subst. Abuse"},{"issue":"15","key":"10.1016\/j.drugalcdep.2020.108366_bib0205","doi-asserted-by":"crossref","first-page":"170","DOI":"10.15288\/jsas.2005.s15.170","article-title":"A structured approach to medical management: a psychosocial intervention to support pharmacotherapy in the treatment of alcohol dependence","author":"Pettinati","year":"2005","journal-title":"J. Stud. Alcohol Suppl."},{"key":"10.1016\/j.drugalcdep.2020.108366_bib0210","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1001\/archpsyc.63.2.219","article-title":"Six-month trial of bupropion with contingency management for cocaine dependence in a methadone-maintained population","volume":"63","author":"Poling","year":"2006","journal-title":"Arch. Gen. Psychiatry"},{"issue":"10","key":"10.1016\/j.drugalcdep.2020.108366_bib0215","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1177\/070674370404901020","article-title":"The effect of quetiapine on cannabis use in 8 psychosis patients with drug dependency","volume":"49","author":"Potvin","year":"2004","journal-title":"Can. J. Psychiatry"},{"issue":"April 1-3","key":"10.1016\/j.drugalcdep.2020.108366_bib0220","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.drugalcdep.2007.11.004","article-title":"Levodopa pharmacotherapy for cocaine dependence: choosing the optimal behavioral therapy platform","volume":"94","author":"Schmitz","year":"2008","journal-title":"Drug Alcohol Depend."},{"issue":"6","key":"10.1016\/j.drugalcdep.2020.108366_bib0225","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1176\/ajp.156.6.876","article-title":"Rapid release of antipsychotic drugs from dopamine D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine","volume":"156","author":"Seeman","year":"1999","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2020.108366_bib0230","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.psychres.2017.01.027","article-title":"Effect of oxytocin pretreatment on cannabis outcomes in a brief motivational intervention","volume":"249","author":"Sherman","year":"2017","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.drugalcdep.2020.108366_bib0235","series-title":"Key Substance Use and Mental Health Indicators in the United States: Results From the 2018 National Survey on Drug Use and Health (HHS Publication No. PEP19-5068, NSDUH Series H-54)","author":"Substance Abuse and Mental Health Services Administration","year":"2019"},{"issue":"December 57-63","key":"10.1016\/j.drugalcdep.2020.108366_bib0240","article-title":"Contingency management with pharmacologic treatment for stimulant use disorders: a review","volume":"111","author":"Tardelli","year":"2018","journal-title":"Behav. Res. Ther."},{"issue":"4","key":"10.1016\/j.drugalcdep.2020.108366_bib0245","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1177\/0269881107073257","article-title":"The safety of quetiapine: results of a post-marketing surveillance study on 1728 patients in England","volume":"21","author":"Twaites","year":"2007","journal-title":"J. Psychopharmacol. (Oxford)"},{"issue":"1","key":"10.1016\/j.drugalcdep.2020.108366_bib0250","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3109\/00952990.2013.819362","article-title":"Treatment of cannabis dependence using escitalopram in combination with cognitive-behavior therapy: a double-blind placebo-controlled study","volume":"40","author":"Weinstein","year":"2014","journal-title":"Am. J. Drug Alcohol Abuse"}],"container-title":["Drug and Alcohol Dependence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871620305317?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871620305317?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T09:13:28Z","timestamp":1759828408000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0376871620305317"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":50,"alternative-id":["S0376871620305317"],"URL":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2020.108366","relation":{},"ISSN":["0376-8716"],"issn-type":[{"value":"0376-8716","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quetiapine treatment for cannabis use disorder","name":"articletitle","label":"Article Title"},{"value":"Drug and Alcohol Dependence","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2020.108366","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108366"}}